Alvotech (ALVO) has released an update.
Alvotech, a global biotech firm, has completed a private debt financing venture to restructure its debt, reduce capital costs, and enhance debt maturity profile. The company secured $965 million, maturing in June 2029, to support ongoing biosimilar development and upcoming product launches. This strategic financial maneuver demonstrates bondholder confidence and bolsters Alvotech’s growth in the biosimilar medicine sector.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
